These partial bindings could be considered insignificant because many studies have reported that partial binding between HepG2 and heterologous monoclonal antibodies often occurs, as the HepG2 cell line does not have specific cancer markers and shares some biological surface proteins expressed in most normal epithelial tissues, lymphatic tissues, and cancer stem cells, including cells of HNSCC, breast, colon, liver, ovarian, pancreatic, and gastric cancer [33,34,35,36]. This evidence concerns the gene PROS1 and cancer.